FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn ...
Medscape4d
FDA OKs Guselkumab for Crohn’s Disease
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
Rheumatology Advisor1d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
WebMD5d
FDA OKs New Crohn’s Treatment You Can Inject at Home
March 24, 2025 – The FDA has approved a new Crohn’s disease treatment called guselkumab, which, unlike similar drugs, can be given via self-injection by patients at home, provided their ...
Health and Me on MSN4d
FDA Approves Tremfya For Active Crohn's Disease
Crohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
Wyoming News5d
FDA Approves Tremfya for Active Crohn Disease in Adults
MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This ...